One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
One thing that is still open after Dr.LeslieOBGYN’s answer:
Whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is?
wendy_avl said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
Adding the part of the answer the thread has not reached. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOP back with an update, since a thread like this is useless without one.
Closing this out. What actually changed my mind was the point about waiting for a trend instead of reading a single measurement, which is embarrassing in hindsight and worth saying anyway.
GenomicsKate said:If two explanations both fit, the useful question is which one predicts something the other does not.
No disagreement, though the timescale matters more than the mechanism here. Most of what looks like a difference in kind turns out to be a difference in how long somebody waited.